DE69625802T2 - Impfstoffe gegen die pest - Google Patents

Impfstoffe gegen die pest

Info

Publication number
DE69625802T2
DE69625802T2 DE69625802T DE69625802T DE69625802T2 DE 69625802 T2 DE69625802 T2 DE 69625802T2 DE 69625802 T DE69625802 T DE 69625802T DE 69625802 T DE69625802 T DE 69625802T DE 69625802 T2 DE69625802 T2 DE 69625802T2
Authority
DE
Germany
Prior art keywords
pct
antigen
pestis
whole
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625802T
Other languages
English (en)
Other versions
DE69625802D1 (de
Inventor
William Titball
Diane Williamson
Emma Leary
Claire Oyston
Marie Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69625802(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9505059.7A external-priority patent/GB9505059D0/en
Priority claimed from GBGB9518946.0A external-priority patent/GB9518946D0/en
Priority claimed from GBGB9524825.8A external-priority patent/GB9524825D0/en
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Publication of DE69625802D1 publication Critical patent/DE69625802D1/de
Application granted granted Critical
Publication of DE69625802T2 publication Critical patent/DE69625802T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69625802T 1995-03-13 1996-03-13 Impfstoffe gegen die pest Expired - Lifetime DE69625802T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9505059.7A GB9505059D0 (en) 1995-03-13 1995-03-13 Vaccines
GBGB9518946.0A GB9518946D0 (en) 1995-09-15 1995-09-15 Vaccines
GBGB9524825.8A GB9524825D0 (en) 1995-12-05 1995-12-05 Vaccines
PCT/GB1996/000571 WO1996028551A1 (en) 1995-03-13 1996-03-13 Vaccines for plague

Publications (2)

Publication Number Publication Date
DE69625802D1 DE69625802D1 (de) 2003-02-20
DE69625802T2 true DE69625802T2 (de) 2003-11-13

Family

ID=27267623

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625802T Expired - Lifetime DE69625802T2 (de) 1995-03-13 1996-03-13 Impfstoffe gegen die pest

Country Status (12)

Country Link
US (1) US5985285A (de)
EP (1) EP0815235B1 (de)
JP (1) JP3813173B2 (de)
CN (1) CN1155707C (de)
AT (1) ATE231184T1 (de)
AU (1) AU710181B2 (de)
CA (1) CA2215203C (de)
DE (1) DE69625802T2 (de)
DK (1) DK0815235T3 (de)
ES (1) ES2185762T3 (de)
PT (1) PT815235E (de)
WO (1) WO1996028551A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0652962T3 (da) * 1992-07-31 1999-08-23 Medeva Holdings Bv Ekspression af rekombinante fusionsproteiner i attenuerede bakterier
AU5597998A (en) * 1996-12-04 1998-06-29 Heska Corporation Recombinant plague vaccine
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
EP1163002B1 (de) * 1999-03-24 2008-08-06 The Secretary of State for Defence Polykationische karbohydrate als immunostimulierende mittel in impstoffen
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
JP2003509046A (ja) * 1999-09-10 2003-03-11 イギリス国 組換え微生物
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
AU780182B2 (en) * 2000-03-22 2005-03-03 Secretary Of State For Defence, The Pharmaceutical composition for administration to mucosal surfaces
US20030219737A1 (en) * 2000-03-28 2003-11-27 Bullard James M. Novel DNA polymerase III holoenzyme delta subunit nucleic acid molecules and proteins
WO2002092769A2 (en) * 2001-05-14 2002-11-21 Replidyne, Inc. System for discovery of agents that block yersinia pestis and pseudomonas aeruginosa dna replication
US6939959B2 (en) * 2001-10-26 2005-09-06 Id Biomedical Corporation Of Washington Efficient protein expression system
GB0220257D0 (en) 2002-08-31 2002-10-09 Secr Defence Vaccine
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition
US7344718B2 (en) * 2003-01-31 2008-03-18 University Of North Dakota Yersinia species compositions
DE602004027940D1 (de) 2003-10-22 2010-08-12 Id Biomedical Corp Quebec Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
AU2004296394A1 (en) * 2003-12-09 2005-06-23 Avant Immunotherapeutics, Inc. Orally-administered live bacterial vaccines for plague
WO2006060728A2 (en) * 2004-12-02 2006-06-08 University Of Chicago Methods and compositions involving lcrv proteins
CN101094685B (zh) * 2004-12-16 2016-01-13 韦克福里斯特大学健康科学院 鞭毛蛋白在鼠疫耶尔森氏菌的免疫疗法中的用途
WO2006066214A2 (en) * 2004-12-16 2006-06-22 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
CN101337069B (zh) * 2005-11-25 2012-07-25 中国药品生物制品检定所 复合鼠疫疫苗及其制备方法
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US7815911B1 (en) * 2006-10-10 2010-10-19 University Of Kentucky Research Foundation Compositions and methods for treating Yersinia pestis infection
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
EP2178558B1 (de) * 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis-antigene, impfstoffzusammensetzungen und zugehörige verfahren
GB0717187D0 (en) * 2007-09-04 2007-10-17 Novartis Ag Compositions comprising yersinia pestis antigens
CN101531710B (zh) * 2009-04-24 2012-05-09 中国疾病预防控制中心传染病预防控制所 rF1抗原及其制备方法与应用
CN101979504A (zh) * 2010-10-26 2011-02-23 中国人民解放军军事医学科学院微生物流行病研究所 鼠疫耶尔森氏菌菌蜕、其制备方法及作为疫苗的应用
CN101985610A (zh) * 2010-10-26 2011-03-16 中国人民解放军军事医学科学院微生物流行病研究所 一种伤寒沙门氏菌菌蜕、制备方法及作为递送系统的应用
US9211327B2 (en) 2011-06-22 2015-12-15 University Of North Dakota Use of YSCF, truncated YSCF and YSCF homologs as adjuvants
US9409956B2 (en) * 2012-05-23 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof
US9328149B2 (en) * 2013-07-12 2016-05-03 The Catholic University Of America Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
RU2671525C2 (ru) * 2015-12-07 2018-11-01 Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации Рекомбинантный вакцинный препарат пролонгированного действия для профилактики чумы у млекопитающих и человека и способ его получения
CN114560932B (zh) * 2022-02-18 2023-09-12 中国人民解放军军事科学院军事医学研究院 一株鼠疫中和抗体及其应用

Also Published As

Publication number Publication date
ES2185762T3 (es) 2003-05-01
JP3813173B2 (ja) 2006-08-23
JPH11501654A (ja) 1999-02-09
DE69625802D1 (de) 2003-02-20
EP0815235B1 (de) 2003-01-15
AU4951196A (en) 1996-10-02
DK0815235T3 (da) 2003-04-22
PT815235E (pt) 2003-06-30
CA2215203A1 (en) 1996-09-19
CN1184505A (zh) 1998-06-10
ATE231184T1 (de) 2003-02-15
EP0815235A1 (de) 1998-01-07
US5985285A (en) 1999-11-16
WO1996028551A1 (en) 1996-09-19
CA2215203C (en) 2008-12-09
CN1155707C (zh) 2004-06-30
AU710181B2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
DE69625802D1 (de) Impfstoffe gegen die pest
RU94046232A (ru) Вакцинная композиция, применение композиции, способы лечения, способ приготовления композиции
FR2620941B1 (fr) Vaccin contenant des adjuvants et des antigenes tumoraux
FI944676A0 (fi) Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä
DE69309479T2 (de) Markiertes monocyte-chemoattractant-proteinmaterial und medizinische anwendung
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
DE60004334D1 (de) Impfstoffzusammensetzung auf basis von partikeln
DE69230855D1 (de) System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
ES2089371T3 (es) Vacuna contra las enfermedades respiratorias para gatos.
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
EA200300535A1 (ru) Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
ATE297985T1 (de) Orale impfstoffe gegen yersinia pestis infektionen
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
Okuda et al. Cytokine and costimulatory factor-encoding plasmids as adjuvants for DNA vaccination
RU2190424C1 (ru) Антигенный состав чумной химической вакцины
RU2039569C1 (ru) Способ профилактики бруцеллеза и кампилобактериоза крупного рогатого скота
UA31873A (uk) Спосіб вакцино-профілактики птиці
Mukerjee et al. Effect of adjuvants on immunization with dengue virus-induced cytotoxic factor
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
Madkour et al. Brucellosis Vaccines in Humans
Tyrrell Humoral and Cellular Aspects of the Response to Infection: The Role of Interferon in the Response to Infection
UA50800C2 (uk) Спосіб вакцинації тварин від інфекційних захворювань
Schubert This is your lung on diesel exhaust

Legal Events

Date Code Title Description
8364 No opposition during term of opposition